Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CHRSthis companyCoherus Oncology, Inc.	$0.81	-0.98×	2.8×	4.05×	-0.72×	-124.2%	57.9%	-425.7%	-403.8%	-279.1%	-151.8%	-81.0%	0.66×	0.29×	-19.95×	1.46×	0.0%	2	-12.02	1	C-
AVTXAvalo Therapeutics, Inc.	$7.04	-3.11×	2.93×	4,125.96×	-2.96×	-86.5%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	4.43	2	B-
CCCCC4 Therapeutics, Inc.	$3.12	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
CDXSCodexis, Inc.	$1.13	-3.26×	2.81×	2.02×	-4.86×	-459.7%	86.7%	-54.5%	-62.5%	-87.0%	-30.6%	-16.8%	1.45×	-0.66×	-7.96×	3.82×	0.0%	3	-6.21	1	D+
IMDXInsight Molecular Diagnostics Inc.	$2.69	-4.55×	-7.26×	56.37×	-4.6×	-189.3%	4.7%	-754.1%	-1238.5%	159.6%	-197.4%	-11.1%	-0.11×	0.17×	-280.53×	1.27×	0.0%	1	-23.74	2	C
IVVDInvivyd, Inc.	$0.58	-8.23×	1.76×	7.96×	-3.99×	1722.3%	93.0%	-104.0%	-98.2%	-21.7%	-22.8%	-13.7%	0.01×	4.45×	0×	7.24×	0.0%	1	-4.47	3	B
Peer median	—	-3.26×	1.76×	7.96×	-3.99×	-187.2%	86.7%	-290.7%	-292.1%	-40.9%	-31.4%	-16.8%	0.03×	0.17×	0×	7.24×	0.0%	2	-4.47	2	—